ArticleClinical ophthalmology (Auckland, N.Z.)2026
Efficacy of Netarsudil in Open and Closed Angle Glaucomas Within the Vietnamese Population: A Single-Center, Retrospective Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the intraocular pressure (IOP)-lowering efficacy and safety of netarsudil, a Rho-associated kinase (ROCK) inhibitor, among eyes with open-angle glaucoma (OAG), combined-mechanism glaucoma (CMG), and angle-closure glaucoma (ACG) in a predominantly Vietnamese population. Patients and Methods: A retrospective chart review was performed of eyes diagnosed with OAG, CMG, or ACG and treated with netarsudil (Rhopressa or Rocklatan) between 2018 and 2024 at a single glaucoma specialty clinic in San Jose, California. Baseline demographics, IOP, visual acuity, and cup-to-disc ratio were collected. The primary outcome was mean IOP reduction at 6 months. Secondary outcomes included discontinuation due to adverse effects and uncontrolled IOP requiring additional therapy or surgery. IOP values were adjusted using an estimated value for medication changes following ROCK inhibitor initiation. Mixed-effects linear regression and parametric survival models were used, adjusting for baseline covariates and IOP. Results: A total of 235 eyes were included: 116 with OAG, 66 with CMG, and 53 with ACG. The mean patient age was 74.9 ± 9.4 years, with 90% identifying as Vietnamese. Mean IOP reduction at 6 months was similar across groups (OAG: 4.2 ± 3.9 mmHg; CMG: 3.4 ± 4.1 mmHg; ACG: 4.3 ± 5.0 mmHg; p>0.05). After adjustment for baseline IOP and covariates, no statistically significant differences were found. Discontinuation due to adverse effects occurred in 16% of OAG, 14% of CMG, and 8% of ACG eyes (p>0.05), with conjunctival hyperemia most common. Rates of uncontrolled IOP were also similar among groups (p>0.05). Conclusion: Netarsudil and its combination therapies demonstrated no significant difference in IOP reduction and tolerability across OAG, CMG, and ACG. These findings support its use as an adjunctive therapy regardless of angle configuration and highlight the need for prospective studies in Asian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.